Response to benralizumab in patients with severe eosinophilic asthma
##plugins.themes.themeEleven.article.main##
Palabras clave
Asthma, Inflammation, Fractional Exhaled Nitric Oxide Testing, Eosinophils, Benralizumab
Resumen
Background: Severe asthma represents a significant public health challenge, and monoclonal antibodies such as benralizumab represent an effective therapeutic option for achieving disease control.
Objective: To evaluate the effectiveness of benralizumab in patients with severe eosinophilic asthma by assessing changes in fractional exhaled nitric oxide (FeNO), peripheral blood eosinophils, symptom control, forced expiratory volume in 1 second (FEV1), and exacerbation rates six months after treatment initiation.
Materials and methods: A prospective observational study was conducted in 11 patients with severe uncontrolled eosinophilic asthma. Clinical outcomes (ACT), quality of life (mini-AQLQ), FEV1, exacerbations, and biomarkers of blood eosinophils and FeNO were assessed at baseline and six months.
Results: After six months of benralizumab therapy, > 90% of patients showed significant improvement in quality of life (mini-AQLQ, p < 0.05), and 72.7% achieved better asthma control (ACT, p < 0.05). Exacerbations decreased by 66.9% (p < 0.05). Blood eosinophils decreased by 97.5% (p < 0.05), FeNO by 57% (p < 0.05), and FEV1 increased by 27.7% (p < 0.05).
Conclusions: Benralizumab demonstrated significant clinical and inflammatory benefits in this cohort, improving biomarkers, lung function, exacerbation rates, and patient-reported outcomes, supporting its effectiveness in real-world management of severe eosinophilic asthma.
Referencias
1. Maldonado-Ríos VA, Ardila-Herrera JC, Galicia-Sánchez LM, et al. Tezepelumab: una nueva opción para el tratamiento del asma grave. Rev Med Inst Mex Seguro Soc. 2023;61(6):841-848. doi: 10.5281/zenodo.10064422.
2. Principe S, Porsbjerg C, Bolm Ditlev S, et al. Treating severe asthma: Targeting the IL-5 pathway. Clin Exp Allergy. 2021;51(8):992-1005. doi: 10.1111/cea.13885.
3. Comité de la Guía Española para el Manejo del Asma. GEMA 5.0. Guía Española para el Manejo del Asma [Internet]. 2021 [citado 10 jul 2024]. Disponible en: https://www.gemasma.com
4. Poto R, Shamji M, Marone G, et al. Neutrophil Extracellular Traps in Asthma: Friends or Foes? Cells. 2022;11(21):3521. doi: 10.3390/cells11213521.
5. Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022;386(2):157-171. doi: 10.1056/NEJMra2032506.
6. Mosnaim G. Asthma in Adults. N Engl J Med. 2023;389(11):1023-1031. doi: 10.1056/NEJMcp2304871.
7. Israel E, Wechsler ME, Jackson DJ, et al. Anti-cytokine biologics for asthma in adults. Lancet. 2025;406(10516):2282-2294. doi: 10.1016/S0140-6736(25)01625-3.
8. D'Aiuto V, Mormile I, Granata F, et al. Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment. Int J Mol Sci. 2025;26(4):1729. doi: 10.3390/ijms26041729.
9. Bourdin A, Brusselle G, Couillard S, et al. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics. J Allergy Clin Immunol Pract. 2024;12(4):809-823. doi: 10.1016/j.jaip.2024.01.023.
10. American Thoracic Society. Asthma Control Test (ACT) [Internet]. New York: ATS; 2024 [citado 10 jul 2024]. Disponible en: https://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/act.php
11. Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14(1):32-8. doi: 10.1034/j.1399-3003.1999.14a08.x.
12. Global Initiative for Asthma (GINA). 2024 GINA Main Report: A Pocket Guide for Asthma Management and Prevention [Internet]. GINA; 2024 [citado 12 oct 2025]. Disponible en: https://ginasthma.org/wp-content/uploads/2024/12/GINA-Summary-Guide-2024-WEB-WMS.pdf
13. Ora J, Giorgino FM, Bettin FR, et al. Pulmonary Function Tests: Easy Interpretation in Three Steps. J Clin Med. 2024;13(13):3655. doi: 10.3390/jcm13133655.
14. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-15. doi: 10.1164/rccm.9120-11ST.
15. Larenas-Linnemann D, Salas-Hernández J, Del Río-Navarro BE, et al. MIA 2021, Manejo Integral del Asma. Lineamientos para México. Rev Alerg Mex. 2021;68 Supl 1:s1-s122. doi: 10.29262/ram.v68i5.880.
16. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8.
17. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1.
18. Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8.
19. Carstens D, Maselli DJ, Mu F, et al. Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2. J Allergy Clin Immunol Pract. 2023;11(7):2150-2161.e4. doi: 10.1016/j.jaip.2023.04.029.
20. Del Mar Sánchez Suárez M, Martín Roldan A, Rojo-Tolosa S, et al. Factors influencing the real-world effectiveness of benralizumab in uncontrolled asthma. Sci Rep. 2025;15(1):21777. doi: 10.1038/s41598-025-07275-0.
21. Reddel H, Bateman E, FitzGerald G, et al; Global Initiative for Asthma. Difficult-To-Treat & Severe Asthma in Adolescent and Adult Patients: Diagnosis and Management. V6.0 [Internet]. Fontana, WI: GINA; 2025 [citado 11 ene 2026]. Disponible en: https://www.ginasthma.org
22. Penz E, Rothe T, Dupont L, et al. Early and Sustained Asthma Control and Remission in Real-World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC-2. Clin Exp Allergy. 2025 Oct 29. doi: 10.1111/cea.70162.
23. Menigoz C, Dirou S, Chambellan A, et al. Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma. J Asthma. 2023;60(6):1162-1170. doi: 10.1080/02770903.2022.2136526.
24. Padilla-Galo A, Moya Carmona I, Ausín P, et al. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study. Respir Res. 2023;24(1):235. doi: 10.1186/s12931-023-02539-7.
25. Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017;376(25):2448-2458. doi: 10.1056/NEJMoa1703501.
26. Soendergaard MB, Hansen S, Håkansson KEJ, et al. Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe Asthma. Allergy. 2025;80(4):986-995. doi: 10.1111/all.16425.
27. Larenas-Linnemann D, Gochicoa-Rangel L, Macías-Weinmann A, et al. Consenso mexicano en relación con la fracción exhalada de óxido nítrico (FeNO) en asma 2020. Rev Alerg Mex. 2020;67 Supl 2:S1-S25. doi: 10.29262/ram.v67i0.760.
28. García-Ramírez UN, Navarrete-Rodríguez EM, Chávez-García AA, et al. Guía práctica de seguimiento y manejo del paciente con asma grave tratado con biológicos. Rev Med Inst Mex Seguro Soc. 2022;60(2):201-210.
##plugins.themes.themeEleven.article.sidebar##
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores conservan sus derechos de autor y otorgan a la Revista Médica del IMSS el derecho de primera publicación. Los artículos se distribuyen bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional, que permite su difusión siempre que se reconozca al autor y la fuente original.